Pau Abrisqueta
@ab_pau
Followers
504
Following
2K
Media
2
Statuses
190
Joined January 2012
Infection AEs CAR vs BsAb LBCL @gloria_iacoboni #ASH25 - 228 pts, 62% CAR-T - pts w/ infx: 62% CAR, 55% BsAb, most bacterial/viral - low incidence fungal (<3%) - similar infx risk up to 12 months, no diff infx-related mortality - prior BsAb = worse infx after CAR #tcellrx #lymsm
1
2
10
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial. - Annals of Oncology
annalsofoncology.org
Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase 3 randomised study in front-...
1
13
30
A review on histiocytic disorders: find here major clinical and pathobiological milestones in Langerhans cell histiocytosis reached in the last two decades. https://t.co/lRba6WWKtQ
1
19
57
🎓 Hoy concluyeron estas ediciones del curso de diagnóstico y tratamiento del #linfoma y #hematopatología de @geltamo. Los casos clínicos presentados por los alumnos han sido realmente interesantes y han generado debates muy enriquecedores. La acogida ha sido excelente!
1
15
34
Ampliamos equipo! Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪 Te apuntas? (Contactar secretaria-hemato@vhio.net)
0
16
22
Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma
aacrjournals.org
Abstract. Purpose: Polatuzumab vedotin (polatuzumab) was approved for upfront treatment of diffuse large B-cell lymphoma (DLBCL) in combination with chemoimmunotherapy (Pola-R-CHP) based on the...
0
15
50
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial | Journal of Clinical Oncology
0
16
40
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from @geltamo
https://t.co/1HNG9H81YZ
0
12
33
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology
ashpublications.org
Key Points. Population-wide introduction of DA-EPOCH-R is associated with improved outcomes in HGBCL-DH-BCL2 with DLBCL morphology.The most notable improve
0
16
62
Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO | Blood Advances | American Society of Hematology
ashpublications.org
Key PointsT/L provides durable responses and good survival in R/R DLBCL ineligible for intensive therapy, regardless of age or comorbidities.Patient select
1
5
15
Come see our poster on CLL Development and Response to early BTK Inhibition in del(13q14) Mice — Poster #1019! #iwcll2025 @gellc @VHIO @sehh_es @SEHHJoven @vallhebron @iwCLL
0
9
23
Control del desarrollo de LLC y respuesta al tratamiento por el sistema immune en ratones con del(13q14) @VHIO @Hemato_Vhebron @sehh_es @SEHHJoven #CLL
0
11
16
“Optimizing” HLH diagnoses in patients with lymphoma https://t.co/73y1b2CKm2
#immunobiologyandimmunotherapy #lymphoidneoplasia #phagocytesgranulocytesandmyelopoiesis
ashpublications.org
In this issue of Blood Advances, Zoref-Lorenz et al1 delve further into the optimized hemophagocytic lymphohistiocytosis (HLH) inflammatory (OHI) index, a
0
13
47
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma | Blood | American Society of Hematology
ashpublications.org
Key Points. Fixed-duration epcoritamab plus R2 showed deep, durable responses with favorable long-term outcomes in R/R FL regardless of risk featuresEpcori
0
8
26
#SAVETHEDATE Reunión del Grupo Español de Leucemia Linfocítica Crónica en el congreso anual de @sehh_es 📆 viernes, 10 octubre 2025 🕖 18:45-20:15h 📍 Palacio de Congresos de Oviedo, Sala 9+10 ¡Te esperamos!
0
8
11
📝 A new study, published in @JCO_ASCO, found that pirtobrutinib improves PFS and TTNT vs IdelaR/BR with a well-tolerated safety profile in cBTKi pretreated patients with CLL/SLL. More news: https://t.co/w5gdqqEJhi
#leusm #MedNews #MedEd
0
4
9
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study https://t.co/KX5X442zPs
0
1
2